Open an account

ProMIS Neurosciences

PMN · NASDAQ

$8.09−$0.14 (−1.70%)TodayMarket closed ·
Prev close $8.23

About PMN

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Employees
6
Headquarters
TORONTO, Ontario
Listed
Apr 3, 2017
Sector
Health Care
Industry
Biotechnology
Website
promisneurosciences.com

PMN key statistics

Market cap
72.55M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
33.99K
Volume
30.26K
Open price
$8.34
High today
$8.65
Low today
$8.06
52 Week high
$27.40
52 Week low
$6.27

ProMIS Neurosciences (PMN) at a glance

ProMIS Neurosciences (PMN) last traded at $8.09, with a market cap of 72.55M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.06 and $8.65. The current price is 0.4% above the day's low and 6.5% below its high.

Volume so far is 30.26K shares, in line with the average of 33.99K shares a day.

Over the past year ProMIS Neurosciences has ranged from $6.27 to $27.40, and now sits 9% of the way up that range.

ProMIS Neurosciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.28 per share against an estimate of -$1.39.

The average analyst price target is $44.37, 448.5% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $44.37
Low
$18.18
Now
$8.09
High
$105.00

PMN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 162.6% on average.

  1. Q3 FY24: reported $10.50 per share against an estimate of -$1.77
  2. Q4 FY24: reported -$0.25 per share against an estimate of -$3.54
  3. Q1 FY25: reported -$5.25 per share against an estimate of -$3.03
  4. Q2 FY25: reported -$7.25 per share against an estimate of -$4.42
  5. Q3 FY25: reported -$6.00 per share against an estimate of -$6.14
  6. Q4 FY25: reported -$6.57 per share against an estimate of -$4.93
  7. Q1 FY26: reported -$1.26 per share against an estimate of -$1.49
  8. Q2 FY26: reported -$1.28 per share against an estimate of -$1.39

PMN news

  • Press releaseGlobe Newswire

    ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Vandana Singh

    Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Market-Moving News for July 28th

  • Press releaseGlobe Newswire

    ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

  • Press releaseGlobe Newswire

    ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

  • Press releaseGlobe Newswire

    ProMIS Neurosciences to Participate in Upcoming Conferences in June

Similar companies

Companies in the same industry as ProMIS Neurosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.